FLAIR-Only Progression in Bevacizumab-Treated Relapsing Glioblastoma Does Not Predict Short Survival

Publisher： Karger

E-ISSN： 1423-0232|85|3|191-195

ISSN： 0030-2414

Source： Oncology, Vol.85, Iss.3, 2013-09, pp. : 191-195

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recurrent glioblastoma: Volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3479-3488

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bevacizumab Improves the Overall and Progression-Free Survival of Patients with Metastatic Colorectal Cancer Treated with 5-Fluorouracil-Based Regimens Irrespective of Baseline Risk

By  

Oncology, Vol. 75, Iss. 3-4, 2008-10 ,pp. : 215-223

Karger

Access to resources Recommend Favorite

Bevacizumab‐induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1456-1462

John Wiley & Sons Inc

Access to resources Recommend Favorite

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population‐based analysis

By  

CANCER, Vol. 119, Iss. 19, 2013-10 ,pp. : 3489-3495

John Wiley & Sons Inc

Access to resources Recommend Favorite

Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme

By  

CANCER, Vol. 121, Iss. 17, 2015-09 ,pp. : 2926-2932

John Wiley & Sons Inc

Access to resources Recommend Favorite